MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 290 filers reported holding MIRATI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | -100.0% | 2 | -92.3% | 0.00% | – |
| Q1 2022 | $2,000 | -99.5% | 26 | -98.9% | 0.00% | -100.0% |
| Q3 2021 | $410,000 | +521.2% | 2,322 | +501.6% | 0.02% | +633.3% |
| Q1 2021 | $66,000 | -82.2% | 386 | -82.8% | 0.00% | -87.5% |
| Q3 2020 | $371,000 | – | 2,239 | +223800.0% | 0.02% | – |
| Q2 2020 | $0 | -100.0% | 1 | -99.7% | 0.00% | -100.0% |
| Q4 2019 | $44,000 | +69.2% | 339 | +1.8% | 0.00% | +50.0% |
| Q3 2019 | $26,000 | -83.1% | 333 | -77.8% | 0.00% | -81.8% |
| Q2 2019 | $154,000 | -7.2% | 1,500 | -33.4% | 0.01% | -15.4% |
| Q1 2019 | $166,000 | +86.5% | 2,252 | +7.9% | 0.01% | +62.5% |
| Q4 2018 | $89,000 | +1.1% | 2,087 | +12.9% | 0.01% | +14.3% |
| Q3 2018 | $88,000 | +1660.0% | 1,848 | +366.7% | 0.01% | +600.0% |
| Q3 2017 | $5,000 | +150.0% | 396 | -38.4% | 0.00% | – |
| Q2 2017 | $2,000 | -66.7% | 643 | -48.2% | 0.00% | -100.0% |
| Q1 2017 | $6,000 | -25.0% | 1,242 | -28.4% | 0.00% | 0.0% |
| Q4 2016 | $8,000 | – | 1,734 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |